This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, S.-h. Articles by Yu-Lee, L.-y. Search for Related Content PubMed PubMed Citation Articles by Lee, S.-h. Articles by Yu-Lee, L.-y.

16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway

¹ Department of Immunology, ² Program in Cell and Molecular Biology, ³ Immunology, Allergy, and Rheumatology Section, Department of Medicine, ⁴ Pulmonary and Critical Care Section, and ⁵ Nephrology Section, Baylor College of Medicine; Departments of ⁶ Molecular Pathology and ⁷ Genitourinary Oncology, M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Li-yuan Yu-Lee, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Phone: 713-798-4770; Fax: 713-798-2050; E-mail: yulee{at}bcm.tmc.edu.

Angiogenesis plays a key role in promoting tumorigenesis and metastasis. Several antiangiogenic factors have been shown to inhibit tumor growth in animal models. Understanding their mechanism of action would allow for better therapeutic application. 16-kDa prolactin (PRL), a NH₂-terminal natural breakdown fragment of the intact 23-kDa PRL, exerts potent antiangiogenic and antitumor activities. The signaling mechanism involved in 16-kDa PRL action in endothelial cells remains unclear. One of the actions of 16-kDa PRL is to attenuate the production of nitric oxide (NO) through the inhibition of inducible NO synthase (iNOS) expression in endothelial cells. To delineate the signaling mechanism from 16-kDa PRL, we examined the effect of 16-kDa PRL on interleukin IL-1ß–inducible iNOS expression, which is regulated by two parallel pathways, one involving IFN regulatory factor 1 (IRF-1) and the other nuclear factor-B (NF-B). Our studies showed that 16-kDa PRL specifically blocked IRF-1 but not NF-B signaling to the iNOS promoter. We found that IL-1ß regulated IRF-1 gene expression through stimulation of p38 mitogen-activated protein kinase (MAPK), which mediated signal transducer and activator of transcription 1 (Stat1) serine phosphorylation and Stat1 nuclear translocation to activate the IRF-1 promoter. 16-kDa PRL effectively inhibited IL-1ß–inducible p38 MAPK phosphorylation, resulting in blocking Stat1 serine phosphorylation, its subsequent nuclear translocation and activation of the Stat1 target gene IRF-1. Thus, 16-kDa PRL inhibits the p38 MAPK/Stat1/IRF-1 pathway to attenuate iNOS/NO production in endothelial cells.

This article has been cited by other articles:

				S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee 16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway Cancer Res., November 15, 2007; 67(22): 11045 - 11053. [Abstract] [Full Text] [PDF]

				N. N.C. Tam, I. Leav, and S.-M. Ho Sex Hormones Induce Direct Epithelial and Inflammation-Mediated Oxidative/Nitrosative Stress That Favors Prostatic Carcinogenesis in the Noble Rat Am. J. Pathol., October 1, 2007; 171(4): 1334 - 1341. [Abstract] [Full Text] [PDF]

				C. Molinari, E. Grossini, D. A. S. G. Mary, F. Uberti, E. Ghigo, F. Ribichini, N. Surico, and G. Vacca Prolactin Induces Regional Vasoconstriction through the {beta}2-Adrenergic and Nitric Oxide Mechanisms Endocrinology, August 1, 2007; 148(8): 4080 - 4090. [Abstract] [Full Text] [PDF]

				Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800. [Abstract] [Full Text] [PDF]